江苏康缘药业股份有限公司第八届董事会第十九次临时会议决议公告

Group 1 - The company held its 19th temporary board meeting on May 30, 2025, with all 9 directors present, and the meeting complied with relevant laws and regulations [1][2][3] - The board approved the proposal to change the legal representative from Chairman Xiao Wei to Director Gao Haixin, which aligns with the Company Law and the company's articles of association [1][3] - The board authorized relevant personnel to handle the business registration change in accordance with regulations [3] Group 2 - The company completed the repurchase and cancellation of all remaining restricted stocks from the 2022 incentive plan on May 29, 2025, reducing the total share capital from 569,459,106 shares to 566,158,806 shares [8][9] - Following the repurchase, the controlling shareholder, Jiangsu Kangyuan Group, saw its shareholding percentage increase from 30.94% to 31.12% without changing the number of shares held [8][10] - This change in shareholding percentage is due to the repurchase and does not affect the company's controlling shareholder or actual controller [10][11]